Literature DB >> 2541655

Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells.

R A Hodge1, R M Perkins.   

Abstract

The metabolism and mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) were studied in herpes simplex virus type 1 (HSV-1)-infected and uninfected MRC-5 cells and compared with those of acyclovir. In uninfected cells incubated with 10 microM acyclonucleoside for 4 h, no phosphorylation of either BRL 39123 or acyclovir was detected. In contrast, in HSV-1-infected cells, both BRL 39123 and acyclovir were phosphorylated up to the triphosphate esters. Phosphorylation of BRL 39123 occurred much more rapidly and proceeded to a greater extent than did that of acyclovir. Furthermore, following the removal of acyclonucleoside from the culture medium, the intracellular triphosphate ester of BRL 39123 was much more stable than was that of acyclovir, the half-lives being about 10 and 0.7 h, respectively. BRL 39123 treatment effectively inhibited the formation of HSV-1 DNA in infected MRC-5 cells, 50% inhibitory concentrations of BRL 39123 and acyclovir being 0.04 microgram/ml (0.16 microM) and 0.15 microgram/ml (0.67 microM), respectively. In addition, BRL 39123 was shown to be more effective than acyclovir at inhibiting viral DNA synthesis following short treatment times, presumably reflecting the greater stability of BRL 39123 triphosphate. Neither BRL 39123 nor acyclovir inhibited cellular DNA synthesis in uninfected cells at concentrations of up to 100 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541655      PMCID: PMC171461          DOI: 10.1128/AAC.33.2.223

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Critical determinants of antiherpes efficacy of buciclovir and related acyclic guanosine analogs.

Authors:  R Datema; A C Ericson; H J Field; A Larsson; K Stenberg
Journal:  Antiviral Res       Date:  1987-07       Impact factor: 5.970

2.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals.

Authors:  M R Boyd; T H Bacon; D Sutton
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

3.  Nucleoside-diphosphate derivatives of 2-deoxy-D-glucose in animal cells.

Authors:  M F Schmidt; R T Schwarz; C Scholtissek
Journal:  Eur J Biochem       Date:  1974-11-01

4.  Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease.

Authors:  T J Hill; H J Field; W A Blyth
Journal:  J Gen Virol       Date:  1975-09       Impact factor: 3.891

5.  Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir.

Authors:  A Larsson; K Stenberg; A C Ericson; U Haglund; W A Yisak; N G Johansson; B Oberg; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

6.  Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines.

Authors:  M R Harnden; R L Jarvest; T H Bacon; M R Boyd
Journal:  J Med Chem       Date:  1987-09       Impact factor: 7.446

7.  Influence of acyclovir and bucyclovir on nucleotide pools in cells infected with herpes simplex virus type 1.

Authors:  A H Karlsson; J G Harmenberg; B E Wahren
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

8.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture.

Authors:  M R Boyd; T H Bacon; D Sutton; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

9.  Nucleoside pools of acyclovir-treated herpes simplex type 1 infected cells.

Authors:  J Harmenberg; G Abele; B Wahren
Journal:  Antiviral Res       Date:  1985-04       Impact factor: 5.970

10.  Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells.

Authors:  D F Smee; R Boehme; M Chernow; B P Binko; T R Matthews
Journal:  Biochem Pharmacol       Date:  1985-04-01       Impact factor: 5.858

View more
  31 in total

1.  Famciclovir for the management of genital herpes simplex in patients with inadequate response to aciclovir or valaciclovir.

Authors:  Stephen L Sacks; Fred Y Aoki
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 2.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

3.  IL-36γ induces a transient HSV-2 resistant environment that protects against genital disease and pathogenesis.

Authors:  Jameson K Gardner; Melissa M Herbst-Kralovetz
Journal:  Cytokine       Date:  2018-08-15       Impact factor: 3.861

4.  Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes.

Authors:  F Diaz-Mitoma; M Ruben; S Sacks; P MacPherson; G Caissie
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

5.  Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus.

Authors:  D L Earnshaw; T H Bacon; S J Darlison; K Edmonds; R M Perkins; R A Vere Hodge
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

6.  The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects.

Authors:  S E Fowles; D M Pierce; W T Prince; D Staniforth
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication.

Authors:  J Neyts; G Andrei; R Snoeck; G Jähne; I Winkler; M Helsberg; J Balzarini; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

8.  Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model.

Authors:  A M Thackray; H J Field
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.

Authors:  E Lin; C Luscombe; D Colledge; Y Y Wang; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  Mode of action of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl) cycloprop-1'-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus.

Authors:  N Ono; S Iwayama; K Suzuki; T Sekiyama; H Nakazawa; T Tsuji; M Okunishi; T Daikoku; Y Nishiyama
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.